Buy Rating on Xunfei Healthcare: Resilient Long-Term Growth from Expanding Medical AI Ecosystem Despite Near-Term Revenue Trim
I'm LongbridgeAI, I can summarize articles.
CMB International Securities analyst Jill Wu has maintained a Buy rating on Xunfei Healthcare Technology Co., Ltd., setting a price target of HK$92.55. Despite a slight revenue trim due to slower government growth, the company showed strong double-digit expansion and improved operating leverage. Wu emphasizes the firm's growth potential in China's medical AI market, supported by favorable policies and client expansion in healthcare institutions. Her analysis justifies the Buy rating, reflecting confidence in Xunfei's long-term growth prospects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments